Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trials

Amita Shukla-Dave, Nancy A. Obuchowski, Thomas L. Chenevert, Sachin Jambawalikar, Lawrence H. Schwartz, Dariya Malyarenko, Wei Huang, Susan M. Noworolski, Robert J. Young, Mark S. Shiroishi, Harrison Kim, Catherine Coolens, Hendrik Laue, Caroline Chung, Mark Rosen, Michael Boss, Edward F. Jackson

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Physiological properties of tumors can be measured both in vivo and noninvasively by diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging. Although these techniques have been used for more than two decades to study tumor diffusion, perfusion, and/or permeability, the methods and studies on how to reduce measurement error and bias in the derived imaging metrics is still lacking in the literature. This is of paramount importance because the objective is to translate these quantitative imaging biomarkers (QIBs) into clinical trials, and ultimately in clinical practice. Standardization of the image acquisition using appropriate phantoms is the first step from a technical performance standpoint. The next step is to assess whether the imaging metrics have clinical value and meet the requirements for being a QIB as defined by the Radiological Society of North America's Quantitative Imaging Biomarkers Alliance (QIBA). The goal and mission of QIBA and the National Cancer Institute Quantitative Imaging Network (QIN) initiatives are to provide technical performance standards (QIBA profiles) and QIN tools for producing reliable QIBs for use in the clinical imaging community. Some of QIBA's development of quantitative diffusion-weighted imaging and dynamic contrast-enhanced QIB profiles has been hampered by the lack of literature for repeatability and reproducibility of the derived QIBs. The available research on this topic is scant and is not in sync with improvements or upgrades in MRI technology over the years. This review focuses on the need for QIBs in oncology applications and emphasizes the importance of the assessment of their reproducibility and repeatability. Level of Evidence: 5. Technical Efficacy Stage: 1. J. Magn. Reson. Imaging 2018.

Original languageEnglish (US)
JournalJournal of Magnetic Resonance Imaging
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Multicenter Studies
Biomarkers
National Cancer Institute (U.S.)
North America
Permeability
Neoplasms
Perfusion
Magnetic Resonance Imaging
Clinical Trials
Technology
Research

Keywords

  • DCE
  • DWI
  • MRI
  • quantitative imaging biomarkers

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trials. / Shukla-Dave, Amita; Obuchowski, Nancy A.; Chenevert, Thomas L.; Jambawalikar, Sachin; Schwartz, Lawrence H.; Malyarenko, Dariya; Huang, Wei; Noworolski, Susan M.; Young, Robert J.; Shiroishi, Mark S.; Kim, Harrison; Coolens, Catherine; Laue, Hendrik; Chung, Caroline; Rosen, Mark; Boss, Michael; Jackson, Edward F.

In: Journal of Magnetic Resonance Imaging, 01.01.2018.

Research output: Contribution to journalArticle

Shukla-Dave, A, Obuchowski, NA, Chenevert, TL, Jambawalikar, S, Schwartz, LH, Malyarenko, D, Huang, W, Noworolski, SM, Young, RJ, Shiroishi, MS, Kim, H, Coolens, C, Laue, H, Chung, C, Rosen, M, Boss, M & Jackson, EF 2018, 'Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trials', Journal of Magnetic Resonance Imaging. https://doi.org/10.1002/jmri.26518
Shukla-Dave, Amita ; Obuchowski, Nancy A. ; Chenevert, Thomas L. ; Jambawalikar, Sachin ; Schwartz, Lawrence H. ; Malyarenko, Dariya ; Huang, Wei ; Noworolski, Susan M. ; Young, Robert J. ; Shiroishi, Mark S. ; Kim, Harrison ; Coolens, Catherine ; Laue, Hendrik ; Chung, Caroline ; Rosen, Mark ; Boss, Michael ; Jackson, Edward F. / Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trials. In: Journal of Magnetic Resonance Imaging. 2018.
@article{bbf4be31c66d4ebb857406a931914696,
title = "Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trials",
abstract = "Physiological properties of tumors can be measured both in vivo and noninvasively by diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging. Although these techniques have been used for more than two decades to study tumor diffusion, perfusion, and/or permeability, the methods and studies on how to reduce measurement error and bias in the derived imaging metrics is still lacking in the literature. This is of paramount importance because the objective is to translate these quantitative imaging biomarkers (QIBs) into clinical trials, and ultimately in clinical practice. Standardization of the image acquisition using appropriate phantoms is the first step from a technical performance standpoint. The next step is to assess whether the imaging metrics have clinical value and meet the requirements for being a QIB as defined by the Radiological Society of North America's Quantitative Imaging Biomarkers Alliance (QIBA). The goal and mission of QIBA and the National Cancer Institute Quantitative Imaging Network (QIN) initiatives are to provide technical performance standards (QIBA profiles) and QIN tools for producing reliable QIBs for use in the clinical imaging community. Some of QIBA's development of quantitative diffusion-weighted imaging and dynamic contrast-enhanced QIB profiles has been hampered by the lack of literature for repeatability and reproducibility of the derived QIBs. The available research on this topic is scant and is not in sync with improvements or upgrades in MRI technology over the years. This review focuses on the need for QIBs in oncology applications and emphasizes the importance of the assessment of their reproducibility and repeatability. Level of Evidence: 5. Technical Efficacy Stage: 1. J. Magn. Reson. Imaging 2018.",
keywords = "DCE, DWI, MRI, quantitative imaging biomarkers",
author = "Amita Shukla-Dave and Obuchowski, {Nancy A.} and Chenevert, {Thomas L.} and Sachin Jambawalikar and Schwartz, {Lawrence H.} and Dariya Malyarenko and Wei Huang and Noworolski, {Susan M.} and Young, {Robert J.} and Shiroishi, {Mark S.} and Harrison Kim and Catherine Coolens and Hendrik Laue and Caroline Chung and Mark Rosen and Michael Boss and Jackson, {Edward F.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/jmri.26518",
language = "English (US)",
journal = "Journal of Magnetic Resonance Imaging",
issn = "1053-1807",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trials

AU - Shukla-Dave, Amita

AU - Obuchowski, Nancy A.

AU - Chenevert, Thomas L.

AU - Jambawalikar, Sachin

AU - Schwartz, Lawrence H.

AU - Malyarenko, Dariya

AU - Huang, Wei

AU - Noworolski, Susan M.

AU - Young, Robert J.

AU - Shiroishi, Mark S.

AU - Kim, Harrison

AU - Coolens, Catherine

AU - Laue, Hendrik

AU - Chung, Caroline

AU - Rosen, Mark

AU - Boss, Michael

AU - Jackson, Edward F.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Physiological properties of tumors can be measured both in vivo and noninvasively by diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging. Although these techniques have been used for more than two decades to study tumor diffusion, perfusion, and/or permeability, the methods and studies on how to reduce measurement error and bias in the derived imaging metrics is still lacking in the literature. This is of paramount importance because the objective is to translate these quantitative imaging biomarkers (QIBs) into clinical trials, and ultimately in clinical practice. Standardization of the image acquisition using appropriate phantoms is the first step from a technical performance standpoint. The next step is to assess whether the imaging metrics have clinical value and meet the requirements for being a QIB as defined by the Radiological Society of North America's Quantitative Imaging Biomarkers Alliance (QIBA). The goal and mission of QIBA and the National Cancer Institute Quantitative Imaging Network (QIN) initiatives are to provide technical performance standards (QIBA profiles) and QIN tools for producing reliable QIBs for use in the clinical imaging community. Some of QIBA's development of quantitative diffusion-weighted imaging and dynamic contrast-enhanced QIB profiles has been hampered by the lack of literature for repeatability and reproducibility of the derived QIBs. The available research on this topic is scant and is not in sync with improvements or upgrades in MRI technology over the years. This review focuses on the need for QIBs in oncology applications and emphasizes the importance of the assessment of their reproducibility and repeatability. Level of Evidence: 5. Technical Efficacy Stage: 1. J. Magn. Reson. Imaging 2018.

AB - Physiological properties of tumors can be measured both in vivo and noninvasively by diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging. Although these techniques have been used for more than two decades to study tumor diffusion, perfusion, and/or permeability, the methods and studies on how to reduce measurement error and bias in the derived imaging metrics is still lacking in the literature. This is of paramount importance because the objective is to translate these quantitative imaging biomarkers (QIBs) into clinical trials, and ultimately in clinical practice. Standardization of the image acquisition using appropriate phantoms is the first step from a technical performance standpoint. The next step is to assess whether the imaging metrics have clinical value and meet the requirements for being a QIB as defined by the Radiological Society of North America's Quantitative Imaging Biomarkers Alliance (QIBA). The goal and mission of QIBA and the National Cancer Institute Quantitative Imaging Network (QIN) initiatives are to provide technical performance standards (QIBA profiles) and QIN tools for producing reliable QIBs for use in the clinical imaging community. Some of QIBA's development of quantitative diffusion-weighted imaging and dynamic contrast-enhanced QIB profiles has been hampered by the lack of literature for repeatability and reproducibility of the derived QIBs. The available research on this topic is scant and is not in sync with improvements or upgrades in MRI technology over the years. This review focuses on the need for QIBs in oncology applications and emphasizes the importance of the assessment of their reproducibility and repeatability. Level of Evidence: 5. Technical Efficacy Stage: 1. J. Magn. Reson. Imaging 2018.

KW - DCE

KW - DWI

KW - MRI

KW - quantitative imaging biomarkers

UR - http://www.scopus.com/inward/record.url?scp=85056736965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056736965&partnerID=8YFLogxK

U2 - 10.1002/jmri.26518

DO - 10.1002/jmri.26518

M3 - Article

C2 - 30451345

AN - SCOPUS:85056736965

JO - Journal of Magnetic Resonance Imaging

JF - Journal of Magnetic Resonance Imaging

SN - 1053-1807

ER -